Company profile
Myriad Genetics, Inc.
NASDAQ: MYGN · Healthcare · Medical - Diagnostics & Research
#171 of 1,418 Healthcare companies by revenue39th-percentile growth
EA Score
67BFH 55DQ 83GM 59SS 85
v0.1 · 65/100 weight · provisional
↑ listing tenure, workforce scale · ↓ return on equity, revenue growth (YoY)
Methodology →Revenue TTM
$829.0M
Rev growth YoY (TTM)
-0.3%
Net income (FY)
-$365.9M
Employees
2,700
as of 2026-08-11
Market cap
$307.0M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$824.5M$824.5M2025
Net income-$365.9M-$365.9M2025
Operating income-$387.2M-$387.2M2025
Total assets$706.6M$706.6M2025
Liabilities$338.6M$338.6M2025
Equity$368.0M$368.0M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Myriad Genetics, Inc.’s revenue?
Myriad Genetics, Inc. booked $824.5M in FY2025 revenue, contracting 1.6% year over year — slower than 61% of Healthcare companies we track, at a -44.4% net margin.
Peers · Healthcare
Varex Imaging Corporation67BVerano Holdings Corp59CArrowhead Pharmaceuticals, Inc.76B+Orthofix Medical Inc.75B+Tilray Brands, Inc.——Caris Life Sciences, Inc.61CNeighbors
Salt Lake →Key facts
CEOSamraat S Raha
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersSalt Lake City, UT
ExchangeNASDAQ: MYGN
Employees2,700
IPO date1995-10-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.